May Adra1, Kenneth R Lawrence. 1. Department of Pharmacy, Tufts-New England Medical Center, Boston, MA 02111-1533, USA. madra@tufts-nemc.org
Abstract
OBJECTIVE: To evaluate the role of trimethoprim/sulfamethoxazole (TMP/SMX) as an alternative to vancomycin for the treatment of severe Staphylococcus aureus infections. DATA SOURCES: Clinical literature was accessed through MEDLINE (1966-February 2003) and EMBASE (1980-February 2003). Key search terms included trimethoprim/sulfamethoxazole combination and Staphylococcus aureus. DATA SYNTHESIS: An evaluation of case reports, case series, and clinical studies focusing on the use of TMP/SMX for treatment of severe S. aureus infections was conducted. The majority of the reports indicate that TMP/SMX may be effective for the treatment of infections due to low bacterial burdens of susceptible strains of S. aureus. CONCLUSIONS: In select infections, TMP/SMX may be a useful alternative to vancomycin for treatment of severe S. aureus infections. Additional randomized studies should be conducted comparing this agent with vancomycin and linezolid.
OBJECTIVE: To evaluate the role of trimethoprim/sulfamethoxazole (TMP/SMX) as an alternative to vancomycin for the treatment of severe Staphylococcus aureus infections. DATA SOURCES: Clinical literature was accessed through MEDLINE (1966-February 2003) and EMBASE (1980-February 2003). Key search terms included trimethoprim/sulfamethoxazole combination and Staphylococcus aureus. DATA SYNTHESIS: An evaluation of case reports, case series, and clinical studies focusing on the use of TMP/SMX for treatment of severe S. aureus infections was conducted. The majority of the reports indicate that TMP/SMX may be effective for the treatment of infections due to low bacterial burdens of susceptible strains of S. aureus. CONCLUSIONS: In select infections, TMP/SMX may be a useful alternative to vancomycin for treatment of severe S. aureus infections. Additional randomized studies should be conducted comparing this agent with vancomycin and linezolid.
Authors: F P N Mollema; J A Severin; J L Nouwen; A Ott; H A Verbrugh; M C Vos Journal: Antimicrob Agents Chemother Date: 2010-06-14 Impact factor: 5.191
Authors: José M Entenza; Andreas Haldimann; Marlyse Giddey; Sergio Lociuro; Stephen Hawser; Philippe Moreillon Journal: Antimicrob Agents Chemother Date: 2009-06-29 Impact factor: 5.191
Authors: Sandeep Chhabra; Janet Newman; Thomas S Peat; Ross T Fernley; Joanne Caine; Jamie S Simpson; James D Swarbrick Journal: Acta Crystallogr Sect F Struct Biol Cryst Commun Date: 2010-04-30
Authors: Sandeep Chhabra; Olan Dolezal; Brett M Collins; Janet Newman; Jamie S Simpson; Ian G Macreadie; Ross Fernley; Thomas S Peat; James D Swarbrick Journal: PLoS One Date: 2012-01-19 Impact factor: 3.240